Editor's Pick

Serum Institute of India applies for trial of another Covid-19 vaccine

30 January 2021, 13:03 PM
UPDATED 30 January 2021, 19:05 PM
INDIA
Star Online Report
SIL-web.jpg
File Photo: Men ride on a motorbike past a supply truck of India's Serum Institute, the world's largest maker of vaccines, which is working on a vaccine against the coronavirus disease (COVID-19) in Pune, India, May 18, 2020. Photo: Reuters/EUAN ROCHA

Serum Institute of India CEO Adar Poonawalla today said his company has applied for the start of trials of another Covid-19 vaccine, Covovax, which it hopes to launch by June.

The SII has already produced Covishield vaccine, co-developed by the University of Oxford and British-Swedish company AstraZeneca. India has purchased 11 million doses of Covishield for the ongoing vaccination drive that began on January 16.

Google News LinkFor all latest news, follow The Daily Star's Google News channel.

Bangladesh has also opted for Covishield for its inoculation drive.

Poonawalla tweeted today: "Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!"

India plans to vaccinate three crore healthcare and frontline workers in the first phase of the vaccination campaign.
Click to comment

Related News